| http://www.w3.org/ns/prov#value | - Forward-looking statements in this news release address our beliefs that bioM??rieux, as our first partner to launch an automated version of our galectin-3 test, is in a position to drive the adoption of galectin-3 testing in Europe; our belief that identifying and risk-stratifying high-risk patients through galectin-3 testing is a potentially valuable and cost-effective tool in a hospital's strat
|
